VANCOUVER, Wash., Aug. 15, 2014 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency virus (HIV), today announced that its August 20, 2014 annual meeting of shareholders will be shared live through a webcast that will allow the public to access the audio portion of the meeting, as well as management's presentation.
The live audio webcast will be held on Wednesday, August 20, 2014 at 1:00 p.m. PT / 4:00 p.m. ET. The webcast can be accessed at http://cytodyn.equisolvewebcast.com/agm-2014 or via the Investors section of CytoDyn's corporate web site at www.cytodyn.com. Web participants are encouraged to go to the web site 15 minutes prior to the start of the event to register, download and install any necessary software. A replay of the webcast will be available until September 20, 2014.
About PRO 140
PRO 140 belongs to a new class of HIV/AIDS therapeutics -- viral-entry inhibitors -- that are intended to protect healthy cells from viral infection. PRO 140 is a humanized monoclonal antibody directed against CCR5, a molecular portal that HIV uses to enter cells.
The Company announced on July 31, 2014 positive interim results from its Phase 2b treatment substitution clinical trial involving patients with HIV. This Phase 2b study was designed to investigate the potential for weekly injections of PRO 140, a fully humanized monoclonal antibody, to substitute for a patient's current drug regimen to allow a drug holiday.
PRO 140 has been the subject of four Phase 1/1b and two Phase 2a clinical trials, each of which demonstrated its ability to significantly reduce HIV viral load in human test subjects, and has also been designated a "fast track" product candidate by the FDA. The PRO 140 antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements as compared to daily drug therapies currently in use.
CytoDyn is a biotechnology company focused on developing subcutaneously delivered humanized cell-specific monoclonal antibodies (mAbs) as entry inhibitors for the treatment and prevention of Human Immunodeficiency Virus (HIV). The Company has one of the leading mAbs under development for HIV infection, PRO 140, which is a Late Stage 2 humanized mAb with demonstrated antiviral activity in man. PRO 140 blocks the HIV co-receptor CCR5 and clinical trial results thus far indicate that it does not affect the normal function of the cell. Results from Phase 1/1b and Phase 2a human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. CytoDyn intends to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV. For more information on the Company please visit www.cytodyn.com. CONTACT: Investor Relations Porter, LeVay & Rose, Inc. Contact: Michael J. Porter, President Office: (212) 546-4700 E-mail: email@example.com
Help employers find you! Check out all the jobs and post your resume.